| 11.86 0.26 (2.24%) | 04-26 14:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 15.1 | 1-year : | 17.63 |
| Resists | First : | 12.93 | Second : | 15.1 |
| Pivot price | 3.27 |
|||
| Supports | First : | 5.02 | Second : | 0.13 |
| MAs | MA(5) : | 9.49 |
MA(20) : | 2.5 |
| MA(100) : | 0.63 |
MA(250) : | 0.49 |
|
| MACD | MACD : | 2.5 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 90.9 |
D(3) : | 83.1 |
| RSI | RSI(14): 96 |
|||
| 52-week | High : | 12.93 | Low : | 0.13 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PIRS ] has closed below upper band by 8.7%. Bollinger Bands are 2791.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.75 - 11.82 | 11.82 - 11.89 |
| Low: | 11.25 - 11.33 | 11.33 - 11.39 |
| Close: | 11.49 - 11.61 | 11.61 - 11.72 |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Thu, 25 Apr 2024
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference - The Globe and Mail
Thu, 25 Apr 2024
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference - The Globe and Mail
Thu, 25 Apr 2024
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference - The Globe and Mail
Wed, 24 Apr 2024
Pieris Pharmaceuticals (NASDAQ:PIRS) Shares Gap Down to $12.00 - MarketBeat
Tue, 23 Apr 2024
Pieris Pharmaceuticals (NASDAQ:PIRS) Sees Large Volume Increase - MarketBeat
Sun, 21 Apr 2024
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 7.4 (%) |
| Held by Institutions | 39.3 (%) |
| Shares Short | 134 (K) |
| Shares Short P.Month | 71 (K) |
| EPS | -0.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.27 |
| Profit Margin | -57.4 % |
| Operating Margin | -422.1 % |
| Return on Assets (ttm) | -14.8 % |
| Return on Equity (ttm) | -89.8 % |
| Qtrly Rev. Growth | -77.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -0.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -43.71 |
| PEG Ratio | 0 |
| Price to Book value | 43.7 |
| Price to Sales | 27.27 |
| Price to Cash Flow | -21.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|